Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Heron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday’s regular session. As of 12:31…
Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?
Kinnate Biopharma Inc's (NASDAQ: KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company.
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) shares moved upwards by 65.6% to $1.01 during Wednesday’s pre-market session. The market value…
Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring
Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its
Benzinga’s Top Ratings Upgrades, Downgrades For September 19, 2023
Upgrades For Methanex Corp (NASDAQ:MEOH), Raymond James upgraded the previous rating of Market Perform to Outperform. For the…
Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?
Kinnate Biopharma Inc (NASDAQ: KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Longeveron Inc. – Subscription Right (NASDAQ:LGVNR) shares increased by 172.7% to $0.01 during Tuesday’s pre-market session. Avinger…